- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
Results
11
0 new
Stocks with plenty of capacity to fund future growth
11 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
NBIX | US$153.29 | 3.9% | 7.6% | US$15.3b | US$168.71 | PE40.2x | E26.3% | n/a | ||
INCY | US$73.77 | 1.7% | 24.7% | US$14.2b | US$79.76 | PE437.5x | E34.3% | n/a | ||
EXEL | US$32.93 | -3.5% | 51.4% | US$9.4b | US$35.93 | PE20.1x | E20.1% | n/a | ||
CORT | US$69.90 | 12.2% | 223.2% | US$6.4b | US$88.25 | PE52.1x | E37.1% | n/a | ||
KRYS | US$156.07 | 0.7% | 39.9% | US$4.5b | US$206.25 | PE85.7x | E36.7% | n/a | ||
ADMA | US$16.10 | -2.9% | 203.8% | US$3.9b | US$24.27 | PE55.9x | E26.7% | n/a | ||
VCEL | US$59.25 | 3.2% | 35.7% | US$2.9b | US$66.13 | PE824.3x | E42.5% | n/a | ||
LGND | US$118.64 | 2.8% | 60.0% | US$2.2b | US$144.00 | PE49.5x | E26.9% | n/a | ||
HRMY | US$39.54 | 4.0% | 26.4% | US$2.2b | US$54.25 | PE18.4x | E29.1% | n/a | ||
CDXC | US$5.88 | -1.7% | 289.4% | US$451.6m | US$7.96 | PE303.1x | E81.8% | n/a | ||
BSEM | US$15.27 | 16.5% | 68.7% | US$249.0m | US$32.50 | PE16x | E33.8% | n/a |
Page 1 of 1